Analyst Reco. Bristol-Myers Squibb Company

Stocks

BMY

US1101221083

Pharmaceuticals

Market Closed - NYSE Other stock markets 21:00:02 10/07/2026 BST			5-day change	1st Jan Change
57.58 ^USD	-0.62%		-0.95%	+6.75%

07-10	Biopharma Pricing Power Seen as Key Swing Factor for Q2 Earnings, BofA Says	MT
07-10	BofA Securities Adjusts Bristol-Myers Squibb Price Target to $66 From $67	MT

Analyst Reco.

07-10	BofA Securities Adjusts Bristol-Myers Squibb Price Target to $66 From $67	MT
07-10	Bristol-Myers Squibb Expects Solid Q2 Ahead of Bigger H2, RBC Says	MT
06-29	Bristol Myers' CELMoD Franchise Remains Underappreciated Ahead of Iberdomide Decision, RBC Says	MT
05-29	Jefferies Adjusts Price Target on Bristol-Myers Squibb to $73 From $70, Maintains Buy Rating	MT
05-12	Daiwa Securities Adjusts Price Target on Bristol-Myers Squibb to $53 From $62, Maintains Neutral Rating	MT
05-05	Bristol Myers Squibb Slips Slightly Despite DZ Bank's Positive Call
05-01	Bristol-Myers Squibb to Stay Range-Bound Until H2 Data, RBC Says	MT
05-01	Citigroup Adjusts Bristol-Myers Squibb Price Target to $66 From $64	MT
05-01	BMO Capital Adjusts Bristol-Myers Squibb Price Target to $60 From $55	MT
04-10	Bristol-Myers Squibb Poised for In-Line Q1 Amid One-Off Volatility, RBC Says	MT
04-09	Biopharma Stocks Largely Exempt From Pharma Tariffs, BofA Says	MT
04-09	BofA Adjusts Price Target on Bristol-Myers Squibb to $67 From $68, Maintains Buy Rating	MT
04-08	Cantor Fitzgerald Lifts Price Target on Bristol-Myers Squibb to $54 From $45, Maintains Neutral Rating	MT
03-17	Jefferies Adjusts Price Target on Bristol-Myers Squibb to $70 From $68, Maintains Buy Rating	MT
03-17	HSBC Adjusts Price Target on Bristol-Myers Squibb to $60 From $53, Maintains Hold Rating	MT
02-25	Bristol-Myers Squibb's Risk/Reward Profile Balanced, RBC Says	MT
02-25	RBC Initiates Bristol-Myers Squibb at Sector Perform With $60 Price Target	MT
02-25	Berenberg Lifts Price Target on Bristol-Myers Squibb to $60 From $57, Keeps Hold Rating	MT
02-23	Piper Sandler Adjusts Price Target on Bristol-Myers Squibb to $75 From $66, Maintains Overweight Rating	MT
02-20	Daiwa Securities Adjusts Price Target on Bristol-Myers Squibb to $62 From $43, Maintains Neutral Rating	MT
02-06	Wells Fargo Adjusts Bristol-Myers Squibb PT to $60 From $55, Maintains Equal Weight Rating	MT
02-06	Citigroup Adjusts Bristol-Myers Squibb PT to $64 From $60, Maintains Neutral Rating	MT
02-06	JPMorgan Adjusts Bristol-Myers Squibb PT to $67 From $65, Maintains Overweight Rating	MT
02-06	Morgan Stanley Lifts Price Target on Bristol-Myers Squibb to $40 From $37, Keeps Underweight Rating	MT
02-06	Goldman Sachs Adjusts Price Target on Bristol-Myers Squibb to $61 From $57, Maintains Neutral Rating	MT